Silvio Bromberg *

Autor invitado por SIIC

Este trabalho contribui para definirmos a influencia do ciclo menstrual sob a analise dos receptores do cancer de mama

PROLIFERAÇÃO CELULAR E (Y) RECEPTORES DO (DEL) CARCINOMA MAMARIO NO (EN EL) CICLO MENSTRUAL

O ciclo menstrual, com suas variações hormonais, afetam a proliferação celular do câncer de mama. Há correlação da progesterona com os índices de proliferação e na fase lútea com a positividade para receptor de estrogênio e progesterona.

*Silvio Bromberg
describe para SIIC los aspectos relevantes de su trabajo
ESTUDO DO ÍNDICE DE PROLIFERAÇAO CELULAR E DOS RECEPTORES DE ESTROGÊNIO E PROGESTERONA EM MULHERES COM CÂNCER DE MAMA, DURANTE AS FASES FOLICULARES E LÚTEA DO CICLO MENSTRUAL
Institución principal de la investigación
*Hospital Albert Einstein, São Paulo, Brasil
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
Axelrod DM, Mendez-Botetvb CJ, Kinne DW, Osborne MP. Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of the menses. Cancer Invest 1988; 6(1):7-14. Badwe RA, Gregory WM, Chaudary MA, Richards MA, Bentley AE, Rubens RD, Fentiman IS. Timing of surgery during menstrual cycle and survival of premenopausal women with operable breast cancer. Lancet 1991; 337(8752):1261-4. Badwe RA, Richards MA, Fentiman IS, Gregory W, Saad Z, Chaudary MA, Bentley A, Rubens RD. Surgical procedures menstrual cycle phase and prognosis in operable breast cancer. Lancet 1991; 338(8770):815-6. Beatson GT. On the treatment of inoperable cases of carcinoma of the mama: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2:104-7. Bergers E, Van Diest PJ, Baak JP. Tumor heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry. J Clin Pathol 1996; 49(11):931-7. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957; 11:359. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status and survival in 24740 breast cancer cases. Cancer 1989; 1:181-87. Chapman JW, Mobbs BG, McCready DR, Lickley HL, Trudeau ME, Hanna W, Kahn HJ, Sawka CD, Fish EB, Pritchard KI. An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. J Steroid Biochem Molec Biol 1996; 57(5/6):323-28. Clarke R, Dickson RB, Lippman ME. Hormonal aspects of breast cancer growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 1992; 12:1-23. Corder AP, Cross M, Julious SA, Mullee MA, Taylor I. The timing of breast cancer surgery withim the menstrual cycle. Postgrad Med J 1994; 70(822):281-4. Dodd LG, Kerns BJ, Dodge RK, Layfield LJ. Intratumoral heretogeneity in primary breast carcinoma: study of concurrent parameters. J Surg Oncol 1997; 64(4):280-7. Donegan WL. Prognostic factors. Stage and receptor status in breast cancer. Cancer 1992; 70(6):1755-64. Donegan WL, Shah D. Prognosis of patients with breast cancer related to the timing of operation. Arch Surg 1993; 128(3):309-13. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 1991; 19:403-10. Fanelli MA, Vargas Roing LM, Gago FE, Tello O, Lucero de Angelis R, Ciocca DR. Estrogen receptors, progesterone receptors and cell proliferation in human breast cancer. Breast Cancer Res Treat 1996; 37(3):217-28. Fentiman IS, Gregory WM, Richards MA. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 344(8919):402. Ferguson JE, Schor AM, Howell A, Ferguson MWJ. Changes in the extracellular matrix of the normal human breast during the menstrual cycle. Cell Tissue Res 1992; 268:167-77. Fisher B, Gunduz N, Costantino J. DNA flow cytometric analysis of primary operable breast cancer. Cancer 1991; 68:1465-71. Gillett CE, Happerfield LC. Breast cancer from clinic to laboratory. Br J Biomed Sci 1997; 54(1):47-56. Goldirsch A, Gelber RD, Forbes J. Timing breast cancer surgery. Lancet 1991; 338:691-2. Goldirsch A, Gelber RD, Castiglione M, O'Neill A. Menstrual cycle and timing of breast surgery in premenopausal node positive breast cancer: results of the International Breast Cancer Study Group Trial VI. Ann Oncol 1997; 8:751-6. Holdaway IM, Mason BH, Lethaby AE, Harman JE, France JT, Knox BS. Characteristics of the menstrual cycle at the time of surgery for breast cancer. Br J Cancer 1997; 75(3):413-6. Holli K, Isola J, Hakama M. Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient: fact or failacy. Br J Cancer 1995; 71:124-7. Jannink I, Risberg B, Van Diest PJ, Baak JP. Heterogeneity of mitotic activity in breast cancer. Histopathology 1996; 29(5):421-8. Khan SA, Gonchoroff NJ, Miller LE. Expression of p52, c-erb-2 and cathepsin during the menstrual cycle in human breast cancers. Ann Surg Oncol 1997; 4(6):462-85. Luqmani YA, Temmim L, Menon A, Ali MA, Parkson AH. Steroid receptor measurement in breast cancer: comparison between ligand binding and enzyme - immunoassay in cytosalic and nuclear extracts. Int J Cancer 1997; 71(4):526-38. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326(26):1756-61. Nikolic Vukosavljevic D, Vasiljevic N, Brankovic Magic M, Polic D. Variations in steroid hormone receptor content throughout age and menopausal periods and menstrual cycle in breast cancer patients. Neoplasma 1996; 43(3):163-9. Olsson H, Jernstron H, Alm P, Kreipe H, Ingvar C, Jonsson PE, Riden S. Proliferation of the breast epithelium in relation to menstrual cycle phase, hormonal use, and reproductive factors. Br Cancer Res Treat 1996; 40:187-96 Powles TJ, Ashley SE, Nash AG. Timing of surgery for breast cancer and menstrual cycle. Lancet 1991; 337:1604. Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recorrence of breast cancer. J Surg 1996;83:1037-46. Romain S, Laine Bidron C, Martin PM, Magdelenat H. Steroid receptor distribuition in 47892 breast cancers: a collaborative study of European laboratories. Eur J Cancer 1995; 31(3):411-7. Russo J, Russo I. Hormonally induced differentiation: a novel aproach to breast cancer prevention. J Cell Biochem Suppl 1995; 22:58-64. Sauerbrei W, Jager W. Timing of breast cancer surgery: some arguments that there is no effect. Ann Oncol 1994; 5(1):25-7.
35. Senie RT, Rosen PP, Rhodes P, Lesser ML. Timing of breast cancer excision during the menstrual cycle influences duration of disease-free survival. Ann Intern Med 1991; 115(5):337-42. Silvestrini R, Daidone MG, Luisi A, Boracchi P, Mezzetti M, Di Fronzo G, Andreola S, Salvadori B, Veronesi V. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer. J Clin Oncol 1995; 13(3):697-704. Stillman B. Cell cycle control of DNA replication. Science 1996;274:1659-64. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. Cell cycle control of BRCA 2. Cancer Res 1996; 56(20):4590-4. Veronesi U, Luini A, Mariani L, Del-Vecchio M, Alvez D, Andreoli C, Giacobone A, Merson M, Pacetti G, Raselli R, Saccozzi R. Effect of menstrual phase on surgical treatment of breast cancer. Lancet 1994; 343(8912):1545-7. Ville Y, Lasry S, Spyratos F, Hacene K, Brunet M. Menstrual status and breast cancer surgery. Breast Cancer Res Treat 1990; 16(2):119-21. Weickel W, beck T, Mitze M, Knapstein PG. Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody ki-67. Breast Cancer Res Treat 1990; 16:192-8. Wobbes T, Thomas CM, Segers MF, Peer PG, Bruggink ED, Beex LV. The phase of the menstrual cycle has no influence on the disease-free survival of patients with mammary carcinoma. Br J Cancer 1994; 69(3):599-600.